Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation

Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, management of aGVHD is important for successful transplantation. Mucosal damage and alteration of the gut microbiota after allo-HSCT ar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood advances 2020-10, Vol.4 (19), p.4607-4617
Hauptverfasser: Yoshifuji, Kota, Inamoto, Kyoko, Kiridoshi, Yuko, Takeshita, Kozue, Sasajima, Satoshi, Shiraishi, Yukiko, Yamashita, Yuko, Nisaka, Yuko, Ogura, Yukari, Takeuchi, Rie, Toya, Takashi, Igarashi, Aiko, Najima, Yuho, Doki, Noriko, Kobayashi, Takeshi, Ohashi, Kazuteru, Suda, Wataru, Atarashi, Koji, Shiota, Atsushi, Hattori, Masahira, Honda, Kenya, Kakihana, Kazuhiko
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4617
container_issue 19
container_start_page 4607
container_title Blood advances
container_volume 4
creator Yoshifuji, Kota
Inamoto, Kyoko
Kiridoshi, Yuko
Takeshita, Kozue
Sasajima, Satoshi
Shiraishi, Yukiko
Yamashita, Yuko
Nisaka, Yuko
Ogura, Yukari
Takeuchi, Rie
Toya, Takashi
Igarashi, Aiko
Najima, Yuho
Doki, Noriko
Kobayashi, Takeshi
Ohashi, Kazuteru
Suda, Wataru
Atarashi, Koji
Shiota, Atsushi
Hattori, Masahira
Honda, Kenya
Kakihana, Kazuhiko
description Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, management of aGVHD is important for successful transplantation. Mucosal damage and alteration of the gut microbiota after allo-HSCT are key factors in the development of aGVHD. We conducted a prospective study to evaluate the ability of prebiotics, which can alleviate mucosal damage and manipulate the gut microbiota, to mitigate posttransplantation complications, including aGVHD. Resistant starch (RS) and a commercially available prebiotics mixture, GFO, were administered to allo-HSCT recipients from pretransplantation conditioning to day 28 after allo-HSCT. Prebiotic intake mitigated mucosal injury and reduced the incidence of all aGVHD grades combined and of aGVHD grades 2 to 4. The cumulative incidence of skin aGVHD was markedly decreased by prebiotics intake. Furthermore, the gut microbial diversity was well maintained and butyrate-producing bacterial population were preserved by prebiotics intake. In addition, the posttransplantation fecal butyrate concentration was maintained or increased more frequently in the prebiotics group. These observations indicate that prebiotic intake may be an effective strategy for preventing aGVHD in allo-HSCT, thereby improving treatment outcomes and the clinical utility of stem cell transplantation approaches. This study was registered on the University Hospital Medical Information Network (UMIN) clinical trials registry (https://www.umin.ac.jp/ctr/index.htm) as #UMIN000027563. •The intake of probiotics shortened the duration of oral mucositis and diarrhea, and reduced the incidence and severity of aGVHD.•The microbial diversity, population of butyrate producers, and butyrate concentration were maintained in patients who consumed prebiotics. [Display omitted]
doi_str_mv 10.1182/bloodadvances.2020002604
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7556149</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2473952920311939</els_id><sourcerecordid>2447547968</sourcerecordid><originalsourceid>FETCH-LOGICAL-c629t-2b92a4a8a2ba8285516fda3fc644fbe03f14a0bb05f8be4961164cf354f92d893</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxSMEolXpV0A-ckmxHeePL0hQUUCqBAc4WxNnvGuU2IvHCeLb49WWhZ44jWX_3pvxvKpigt8IMcjX4xzjBNMGwSLdSC4557Lj6kl1KVXf1Lpt-qfns9QX1TXR9wKJvmtaLZ9XF43UWvSSX1Y_vyQcfczeEjukmNFmBjvwgUq1a0a2S-ByvWGilep9LPeTJwRCBmEqGiRMG7K8L-ia2eJtikdHYD4wyrgwi_PMcoJAhxlChuxjeFE9czATXj_Uq-rb3fuvtx_r-88fPt2-va9tJ3Wu5aglKBhAjjDIoW1F5yZonO2UciPyxgkFfBx564YRle6E6JR1TaucltOgm6vqzcn3sI4LThZDGWQ2h-QXSL9MBG8evwS_N7u4mb5tO6GOBq8eDFL8sSJls3g6_ggCxpWMVKpvVa-7oaDDCS0bIErozm0EN8fozKPozN_oivTlv2OehX-CKsC7E4BlWZvHZMh6LDaTTyUzM0X__y6_AWVGtCw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2447547968</pqid></control><display><type>article</type><title>Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Yoshifuji, Kota ; Inamoto, Kyoko ; Kiridoshi, Yuko ; Takeshita, Kozue ; Sasajima, Satoshi ; Shiraishi, Yukiko ; Yamashita, Yuko ; Nisaka, Yuko ; Ogura, Yukari ; Takeuchi, Rie ; Toya, Takashi ; Igarashi, Aiko ; Najima, Yuho ; Doki, Noriko ; Kobayashi, Takeshi ; Ohashi, Kazuteru ; Suda, Wataru ; Atarashi, Koji ; Shiota, Atsushi ; Hattori, Masahira ; Honda, Kenya ; Kakihana, Kazuhiko</creator><creatorcontrib>Yoshifuji, Kota ; Inamoto, Kyoko ; Kiridoshi, Yuko ; Takeshita, Kozue ; Sasajima, Satoshi ; Shiraishi, Yukiko ; Yamashita, Yuko ; Nisaka, Yuko ; Ogura, Yukari ; Takeuchi, Rie ; Toya, Takashi ; Igarashi, Aiko ; Najima, Yuho ; Doki, Noriko ; Kobayashi, Takeshi ; Ohashi, Kazuteru ; Suda, Wataru ; Atarashi, Koji ; Shiota, Atsushi ; Hattori, Masahira ; Honda, Kenya ; Kakihana, Kazuhiko</creatorcontrib><description>Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, management of aGVHD is important for successful transplantation. Mucosal damage and alteration of the gut microbiota after allo-HSCT are key factors in the development of aGVHD. We conducted a prospective study to evaluate the ability of prebiotics, which can alleviate mucosal damage and manipulate the gut microbiota, to mitigate posttransplantation complications, including aGVHD. Resistant starch (RS) and a commercially available prebiotics mixture, GFO, were administered to allo-HSCT recipients from pretransplantation conditioning to day 28 after allo-HSCT. Prebiotic intake mitigated mucosal injury and reduced the incidence of all aGVHD grades combined and of aGVHD grades 2 to 4. The cumulative incidence of skin aGVHD was markedly decreased by prebiotics intake. Furthermore, the gut microbial diversity was well maintained and butyrate-producing bacterial population were preserved by prebiotics intake. In addition, the posttransplantation fecal butyrate concentration was maintained or increased more frequently in the prebiotics group. These observations indicate that prebiotic intake may be an effective strategy for preventing aGVHD in allo-HSCT, thereby improving treatment outcomes and the clinical utility of stem cell transplantation approaches. This study was registered on the University Hospital Medical Information Network (UMIN) clinical trials registry (https://www.umin.ac.jp/ctr/index.htm) as #UMIN000027563. •The intake of probiotics shortened the duration of oral mucositis and diarrhea, and reduced the incidence and severity of aGVHD.•The microbial diversity, population of butyrate producers, and butyrate concentration were maintained in patients who consumed prebiotics. [Display omitted]</description><identifier>ISSN: 2473-9529</identifier><identifier>EISSN: 2473-9537</identifier><identifier>DOI: 10.1182/bloodadvances.2020002604</identifier><identifier>PMID: 32991720</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Gastrointestinal Microbiome ; Graft vs Host Disease - prevention &amp; control ; Hematopoietic Stem Cell Transplantation ; Humans ; Prebiotics ; Prospective Studies ; Transplantation</subject><ispartof>Blood advances, 2020-10, Vol.4 (19), p.4607-4617</ispartof><rights>2020 American Society of Hematology</rights><rights>2020 by The American Society of Hematology.</rights><rights>2020 by The American Society of Hematology 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c629t-2b92a4a8a2ba8285516fda3fc644fbe03f14a0bb05f8be4961164cf354f92d893</citedby><cites>FETCH-LOGICAL-c629t-2b92a4a8a2ba8285516fda3fc644fbe03f14a0bb05f8be4961164cf354f92d893</cites><orcidid>0000-0001-5422-0736 ; 0000-0002-7436-972X ; 0000-0001-5062-5795 ; 0000-0002-2861-9724</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556149/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556149/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32991720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshifuji, Kota</creatorcontrib><creatorcontrib>Inamoto, Kyoko</creatorcontrib><creatorcontrib>Kiridoshi, Yuko</creatorcontrib><creatorcontrib>Takeshita, Kozue</creatorcontrib><creatorcontrib>Sasajima, Satoshi</creatorcontrib><creatorcontrib>Shiraishi, Yukiko</creatorcontrib><creatorcontrib>Yamashita, Yuko</creatorcontrib><creatorcontrib>Nisaka, Yuko</creatorcontrib><creatorcontrib>Ogura, Yukari</creatorcontrib><creatorcontrib>Takeuchi, Rie</creatorcontrib><creatorcontrib>Toya, Takashi</creatorcontrib><creatorcontrib>Igarashi, Aiko</creatorcontrib><creatorcontrib>Najima, Yuho</creatorcontrib><creatorcontrib>Doki, Noriko</creatorcontrib><creatorcontrib>Kobayashi, Takeshi</creatorcontrib><creatorcontrib>Ohashi, Kazuteru</creatorcontrib><creatorcontrib>Suda, Wataru</creatorcontrib><creatorcontrib>Atarashi, Koji</creatorcontrib><creatorcontrib>Shiota, Atsushi</creatorcontrib><creatorcontrib>Hattori, Masahira</creatorcontrib><creatorcontrib>Honda, Kenya</creatorcontrib><creatorcontrib>Kakihana, Kazuhiko</creatorcontrib><title>Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation</title><title>Blood advances</title><addtitle>Blood Adv</addtitle><description>Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, management of aGVHD is important for successful transplantation. Mucosal damage and alteration of the gut microbiota after allo-HSCT are key factors in the development of aGVHD. We conducted a prospective study to evaluate the ability of prebiotics, which can alleviate mucosal damage and manipulate the gut microbiota, to mitigate posttransplantation complications, including aGVHD. Resistant starch (RS) and a commercially available prebiotics mixture, GFO, were administered to allo-HSCT recipients from pretransplantation conditioning to day 28 after allo-HSCT. Prebiotic intake mitigated mucosal injury and reduced the incidence of all aGVHD grades combined and of aGVHD grades 2 to 4. The cumulative incidence of skin aGVHD was markedly decreased by prebiotics intake. Furthermore, the gut microbial diversity was well maintained and butyrate-producing bacterial population were preserved by prebiotics intake. In addition, the posttransplantation fecal butyrate concentration was maintained or increased more frequently in the prebiotics group. These observations indicate that prebiotic intake may be an effective strategy for preventing aGVHD in allo-HSCT, thereby improving treatment outcomes and the clinical utility of stem cell transplantation approaches. This study was registered on the University Hospital Medical Information Network (UMIN) clinical trials registry (https://www.umin.ac.jp/ctr/index.htm) as #UMIN000027563. •The intake of probiotics shortened the duration of oral mucositis and diarrhea, and reduced the incidence and severity of aGVHD.•The microbial diversity, population of butyrate producers, and butyrate concentration were maintained in patients who consumed prebiotics. [Display omitted]</description><subject>Gastrointestinal Microbiome</subject><subject>Graft vs Host Disease - prevention &amp; control</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Prebiotics</subject><subject>Prospective Studies</subject><subject>Transplantation</subject><issn>2473-9529</issn><issn>2473-9537</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9v1DAQxSMEolXpV0A-ckmxHeePL0hQUUCqBAc4WxNnvGuU2IvHCeLb49WWhZ44jWX_3pvxvKpigt8IMcjX4xzjBNMGwSLdSC4557Lj6kl1KVXf1Lpt-qfns9QX1TXR9wKJvmtaLZ9XF43UWvSSX1Y_vyQcfczeEjukmNFmBjvwgUq1a0a2S-ByvWGilep9LPeTJwRCBmEqGiRMG7K8L-ia2eJtikdHYD4wyrgwi_PMcoJAhxlChuxjeFE9czATXj_Uq-rb3fuvtx_r-88fPt2-va9tJ3Wu5aglKBhAjjDIoW1F5yZonO2UciPyxgkFfBx564YRle6E6JR1TaucltOgm6vqzcn3sI4LThZDGWQ2h-QXSL9MBG8evwS_N7u4mb5tO6GOBq8eDFL8sSJls3g6_ggCxpWMVKpvVa-7oaDDCS0bIErozm0EN8fozKPozN_oivTlv2OehX-CKsC7E4BlWZvHZMh6LDaTTyUzM0X__y6_AWVGtCw</recordid><startdate>20201013</startdate><enddate>20201013</enddate><creator>Yoshifuji, Kota</creator><creator>Inamoto, Kyoko</creator><creator>Kiridoshi, Yuko</creator><creator>Takeshita, Kozue</creator><creator>Sasajima, Satoshi</creator><creator>Shiraishi, Yukiko</creator><creator>Yamashita, Yuko</creator><creator>Nisaka, Yuko</creator><creator>Ogura, Yukari</creator><creator>Takeuchi, Rie</creator><creator>Toya, Takashi</creator><creator>Igarashi, Aiko</creator><creator>Najima, Yuho</creator><creator>Doki, Noriko</creator><creator>Kobayashi, Takeshi</creator><creator>Ohashi, Kazuteru</creator><creator>Suda, Wataru</creator><creator>Atarashi, Koji</creator><creator>Shiota, Atsushi</creator><creator>Hattori, Masahira</creator><creator>Honda, Kenya</creator><creator>Kakihana, Kazuhiko</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5422-0736</orcidid><orcidid>https://orcid.org/0000-0002-7436-972X</orcidid><orcidid>https://orcid.org/0000-0001-5062-5795</orcidid><orcidid>https://orcid.org/0000-0002-2861-9724</orcidid></search><sort><creationdate>20201013</creationdate><title>Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation</title><author>Yoshifuji, Kota ; Inamoto, Kyoko ; Kiridoshi, Yuko ; Takeshita, Kozue ; Sasajima, Satoshi ; Shiraishi, Yukiko ; Yamashita, Yuko ; Nisaka, Yuko ; Ogura, Yukari ; Takeuchi, Rie ; Toya, Takashi ; Igarashi, Aiko ; Najima, Yuho ; Doki, Noriko ; Kobayashi, Takeshi ; Ohashi, Kazuteru ; Suda, Wataru ; Atarashi, Koji ; Shiota, Atsushi ; Hattori, Masahira ; Honda, Kenya ; Kakihana, Kazuhiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c629t-2b92a4a8a2ba8285516fda3fc644fbe03f14a0bb05f8be4961164cf354f92d893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Gastrointestinal Microbiome</topic><topic>Graft vs Host Disease - prevention &amp; control</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Prebiotics</topic><topic>Prospective Studies</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshifuji, Kota</creatorcontrib><creatorcontrib>Inamoto, Kyoko</creatorcontrib><creatorcontrib>Kiridoshi, Yuko</creatorcontrib><creatorcontrib>Takeshita, Kozue</creatorcontrib><creatorcontrib>Sasajima, Satoshi</creatorcontrib><creatorcontrib>Shiraishi, Yukiko</creatorcontrib><creatorcontrib>Yamashita, Yuko</creatorcontrib><creatorcontrib>Nisaka, Yuko</creatorcontrib><creatorcontrib>Ogura, Yukari</creatorcontrib><creatorcontrib>Takeuchi, Rie</creatorcontrib><creatorcontrib>Toya, Takashi</creatorcontrib><creatorcontrib>Igarashi, Aiko</creatorcontrib><creatorcontrib>Najima, Yuho</creatorcontrib><creatorcontrib>Doki, Noriko</creatorcontrib><creatorcontrib>Kobayashi, Takeshi</creatorcontrib><creatorcontrib>Ohashi, Kazuteru</creatorcontrib><creatorcontrib>Suda, Wataru</creatorcontrib><creatorcontrib>Atarashi, Koji</creatorcontrib><creatorcontrib>Shiota, Atsushi</creatorcontrib><creatorcontrib>Hattori, Masahira</creatorcontrib><creatorcontrib>Honda, Kenya</creatorcontrib><creatorcontrib>Kakihana, Kazuhiko</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshifuji, Kota</au><au>Inamoto, Kyoko</au><au>Kiridoshi, Yuko</au><au>Takeshita, Kozue</au><au>Sasajima, Satoshi</au><au>Shiraishi, Yukiko</au><au>Yamashita, Yuko</au><au>Nisaka, Yuko</au><au>Ogura, Yukari</au><au>Takeuchi, Rie</au><au>Toya, Takashi</au><au>Igarashi, Aiko</au><au>Najima, Yuho</au><au>Doki, Noriko</au><au>Kobayashi, Takeshi</au><au>Ohashi, Kazuteru</au><au>Suda, Wataru</au><au>Atarashi, Koji</au><au>Shiota, Atsushi</au><au>Hattori, Masahira</au><au>Honda, Kenya</au><au>Kakihana, Kazuhiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation</atitle><jtitle>Blood advances</jtitle><addtitle>Blood Adv</addtitle><date>2020-10-13</date><risdate>2020</risdate><volume>4</volume><issue>19</issue><spage>4607</spage><epage>4617</epage><pages>4607-4617</pages><issn>2473-9529</issn><eissn>2473-9537</eissn><abstract>Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, management of aGVHD is important for successful transplantation. Mucosal damage and alteration of the gut microbiota after allo-HSCT are key factors in the development of aGVHD. We conducted a prospective study to evaluate the ability of prebiotics, which can alleviate mucosal damage and manipulate the gut microbiota, to mitigate posttransplantation complications, including aGVHD. Resistant starch (RS) and a commercially available prebiotics mixture, GFO, were administered to allo-HSCT recipients from pretransplantation conditioning to day 28 after allo-HSCT. Prebiotic intake mitigated mucosal injury and reduced the incidence of all aGVHD grades combined and of aGVHD grades 2 to 4. The cumulative incidence of skin aGVHD was markedly decreased by prebiotics intake. Furthermore, the gut microbial diversity was well maintained and butyrate-producing bacterial population were preserved by prebiotics intake. In addition, the posttransplantation fecal butyrate concentration was maintained or increased more frequently in the prebiotics group. These observations indicate that prebiotic intake may be an effective strategy for preventing aGVHD in allo-HSCT, thereby improving treatment outcomes and the clinical utility of stem cell transplantation approaches. This study was registered on the University Hospital Medical Information Network (UMIN) clinical trials registry (https://www.umin.ac.jp/ctr/index.htm) as #UMIN000027563. •The intake of probiotics shortened the duration of oral mucositis and diarrhea, and reduced the incidence and severity of aGVHD.•The microbial diversity, population of butyrate producers, and butyrate concentration were maintained in patients who consumed prebiotics. [Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32991720</pmid><doi>10.1182/bloodadvances.2020002604</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-5422-0736</orcidid><orcidid>https://orcid.org/0000-0002-7436-972X</orcidid><orcidid>https://orcid.org/0000-0001-5062-5795</orcidid><orcidid>https://orcid.org/0000-0002-2861-9724</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2473-9529
ispartof Blood advances, 2020-10, Vol.4 (19), p.4607-4617
issn 2473-9529
2473-9537
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7556149
source MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Gastrointestinal Microbiome
Graft vs Host Disease - prevention & control
Hematopoietic Stem Cell Transplantation
Humans
Prebiotics
Prospective Studies
Transplantation
title Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T23%3A12%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prebiotics%20protect%20against%20acute%20graft-versus-host%20disease%20and%20preserve%20the%20gut%20microbiota%20in%20stem%20cell%20transplantation&rft.jtitle=Blood%20advances&rft.au=Yoshifuji,%20Kota&rft.date=2020-10-13&rft.volume=4&rft.issue=19&rft.spage=4607&rft.epage=4617&rft.pages=4607-4617&rft.issn=2473-9529&rft.eissn=2473-9537&rft_id=info:doi/10.1182/bloodadvances.2020002604&rft_dat=%3Cproquest_pubme%3E2447547968%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2447547968&rft_id=info:pmid/32991720&rft_els_id=S2473952920311939&rfr_iscdi=true